IGF-1 LR3 is the most pro-growth version of this hormone family a chemist can build. Long-lasting. Almost no buffering by the body's normal carrier proteins. Direct, sustained signaling on a pathway that, in large population studies, tracks with cancer incidence. The published preclinical literature, regulatory status, and central cancer-biology concern are reviewed below.
IGF-1 LR3 is a lab-made 83-amino-acid form of human IGF-1, the hormone your liver makes in response to growth hormone. A 13-residue tail and one swapped amino acid cut its grip on carrier proteins, which normally hold 95%+ of the natural form.
So more LR3 stays free and active. No human RCT in healthy adults has been published since 2020. WADA bans it under S2.3, and only mecasermin is approved, for severe pediatric deficiency.
What is IGF-1 LR3?
LR3 is a synthetic 83-amino-acid version of human insulin-like growth factor 1, a hormone the liver produces in response to growth hormone signaling. The natural version is 70 amino acids. LR3 incorporates two structural modifications:
- A 13-amino-acid N-terminal extension (the "Long"). Originally derived from porcine growth hormone sequence. This extension reduces IGFBP binding.
- An arginine substitution at position 3 (the "R3"). Arginine replaces the native glutamate. This substitution reduces carrier-protein binding affinity by orders of magnitude.
The combined effect is a peptide that circulates less bound, for longer, with more free receptor occupancy. A 2023 production study by Lu and colleagues showed LR3 matches the native form for cell-proliferation activity in vitro.
In animals, that extended free fraction becomes sustained receptor signaling, with none of the damping IGFBP sequestration normally provides.
Native version vs LR3 vs mecasermin
Three molecules in this family get confused. They aren't the same thing.
- Native version. The 70-amino-acid peptide produced endogenously by the liver. Over 95% is bound to carrier proteins in circulation.
- Mecasermin (Increlex). Recombinant native version, same 70-amino-acid sequence. FDA-approved in 2005 for severe pediatric deficiency. Dosed twice daily by injection. The only FDA-approved therapy in this family.
- LR3. The 83-residue engineered version with the front-end tail and the position-3 swap. Not FDA-approved. Sold as a research reagent.
The mecasermin prescribing information shows what a controlled IGF-1-axis therapy looks like. It carries warnings for raised intracranial pressure, slipped capital femoral epiphysis and scoliosis.
Those effects were documented in closely monitored pediatric patients, dosed twice daily, on the heavily buffered native form. Active or suspected malignancy is a listed contraindication, which reflects the cancer-biology concern below.
IGF-1 LR3 was developed as a tool compound for studying IGF-1 receptor signaling without binding-protein confounders. Its diversion to the grey-market muscle-growth space is a separate phenomenon, and one for which the published clinical evidence base is essentially non-existent.
— WTBP Research Team, reading the IGF-1 LR3 literature
What the 2020–2026 literature shows
The recent peer-reviewed record on LR3 is sparse, and almost all of it is in animals. We think four findings are worth your time.
Fetal heart growth in sheep, 2020. Jonker and colleagues showed LR3 infusion grew new heart-muscle cells and increased fetal sheep heart mass, with matching blood-vessel growth.
That supports a use in fetal-growth restriction. Fetal heart growth isn't adult exercise adaptation, and the paper doesn't endorse chronic adult use.
Fetal pancreas defects, 2021 and 2023. Two White-group papers found a one-week LR3 infusion in fetal sheep cut insulin output, and the defect persisted in isolated pancreatic islets.
A 2023 follow-up found a 90-minute exposure caused no lasting defect. The authors flag long-term use as the concern.
That concern lands hardest on chronic adult muscle-growth use, where sustained exposure is the entire point.
Alzheimer's mouse model, 2024. A seven-month nasal-spray LR3 study in 5XFAD male mice by Engel and colleagues showed amyloid plaque shifts and better body composition.
The treatment failed to preserve cognitive function, and the authors didn't back LR3 as an Alzheimer's monotherapy. It's the only recent chronic LR3 study in an adult-mouse disease model. Plaque biology shifted. Cognition didn't.
Where this falls short. Only four preclinical papers in 2020–2026, and none in healthy adult humans.
The most rigorous chronic-exposure finding is the White-group pancreas defect. That one is itself a safety signal, and the authors cite it as a reason for caution.
Human clinical evidence (and why there isn't any)
There are zero human RCTs of LR3 for muscle-mass, body-composition, senescence, or tissue-repair endpoints, or any other use in healthy adults during 2020–2026. No FDA IND on public record. No industry pipeline for any consumer or performance use.
The FDA-approved record in this family is mecasermin, the native version, for severe pediatric deficiency. That isn't the grey-market use LR3 gets marketed for.
Bodybuilding-community claims rest on extrapolation from the broader biology, not on LR3 trial data. The biology is plausible. The trials that would back chronic adult use are what's missing.
GH-axis alternatives
Peptriva does not stock IGF-1 LR3 — the cancer-axis concern at chronic adult administration is the reason. The upstream GH-axis catalog (CJC-1295, ipamorelin, tesamorelin) engages the GH/IGF-1 axis while preserving physiological negative-feedback regulation. Tesamorelin is the only FDA-approved peptide in this category. third-party tested reference compounds, COA per lot.
The cancer-biology concern at the center
This growth-factor pathway is one of the most-studied in cancer biology. Higher circulating levels of the native hormone track with increased risk of several cancers in large long-term epidemiological studies: breast, prostate, colorectal and lung.
Signaling through the pathway switches on proliferative programs, PI3K/AKT and MAPK/ERK. It also suppresses apoptosis and promotes tumor angiogenesis.
Multiple companies have developed blockers of this pathway as oncology candidates. The direction of travel in that field is inhibition, not amplification.
Against that background, LR3 is the most pro-mitogenic configuration of the pathway pharmacology can produce. The endogenous form circulates 95%+ bound to carrier proteins.
Mecasermin is dosed twice daily in monitored pediatric patients precisely because that buffer keeps the free fraction short-lived. LR3 was engineered to evade that throttle, producing sustained unbuffered receptor signaling no natural state replicates.
To be precise: no human RCT quantifies the cancer risk of chronic adult LR3 use. We want to be exact about where the concern comes from.
It's inferred from two things. Population data linking endogenous hormone levels to cancer incidence, and the pharmacology, which produces higher and longer IGF-1R signaling than the native form.
The FDA prescribing information for mecasermin contraindicates active or suspected malignancy for the native, buffered form. LR3 amplifies the same signal.
Chronic exogenous IGF-1R activation via a long-half-life IGF-1 analog with reduced binding-protein sequestration is the worst-case configuration from a cancer-surveillance standpoint. The absence of human RCT data quantifying this risk is the central gap in the literature on this compound.
— WTBP Research Team, reading the IGF-1 LR3 literature
Other risks worth naming
- Hypoglycemia. The IGF-1 axis has insulin-like receptor cross-reactivity; preclinical and mecasermin clinical data document the potential for significant blood glucose reductions, with risk compounded by concurrent insulin or oral hypoglycemic agents.
- Pancreatic islet defects from chronic exposure. A one-week LR3 infusion in fetal sheep produced lasting impairment in isolated pancreatic islets (White et al., 2021). Implications for chronic adult mammalian models remain uncharacterized.
- Acromegaly-spectrum effects. Sustained IGF-1R overactivation is mechanistically related to acromegalic pathology — soft-tissue overgrowth, skeletal changes, and cardiac hypertrophy.
- Pharmacodynamic interactions with insulin, oral hypoglycemics, growth hormone, and other GH-axis research compounds (CJC-1295, tesamorelin, ipamorelin) have been reported to compound metabolic effects.
- Identity and purity risk. LR3 is an 83-residue recombinant peptide requiring expression system production and correct disulfide folding. Grey-market material has no characterized purity or sequence confirmation.
Where LR3 sits relative to upstream GH-axis peptides
Our GH-axis overview covers the broader family. The comparison that matters for LR3 is against upstream releasers, which nudge the body into making its own growth hormone under normal regulation.
- CJC-1295. A growth-hormone-releasing peptide. Triggers a natural GH pulse and natural hormone production, with the body's feedback loops still working.
- Ipamorelin. A selective ghrelin-pathway peptide. Releases pituitary GH without raising cortisol or prolactin.
- Tesamorelin. A stabilized GH-releasing peptide. FDA-approved for HIV-associated lipodystrophy. The only FDA-approved peptide in this category, with Phase III data behind its approved use.
Here's the mechanistic contrast. Upstream releasers keep the natural GH pulse pattern and the endocrine feedback loops intact. LR3 bypasses that architecture entirely.
Keeping physiological feedback comes with a better-characterized safety profile than switching on the receptor directly. For tissue-repair and GH-axis research, BPC-157 and tesamorelin sit on more conservative pathways. Peptriva stocks both, and doesn't stock LR3.
Regulatory status and WADA
- FDA (US): Not approved for any use. The native version (mecasermin / Increlex) is approved for severe pediatric deficiency. LR3 is a different molecule and isn't approved.
- EMA (EU): Not approved.
- WADA: Explicitly prohibited under category S2.3 ("Growth factors and growth factor modulators"), both in-competition and out-of-competition. The WADA Prohibited List names this hormone and its analogs explicitly. One of the clearest prohibitions for any research peptide. Athletes face sanctions for documented use.
- Sale as a research reagent in the U.S. is legal when labeled for laboratory use only. Sale or marketing as a human therapy, with dosing instructions or efficacy claims, is illegal and draws FDA enforcement.
Pricing benchmarks for LR3 in 2026
LR3 pricing swings more than most peptides, because making it correctly is hard. It's 83 residues with disulfide bonds, and recombinant production beats chemical synthesis here.
- 1 mg vial from a legitimate research-reagent supplier: $100–$250.
- 1 mg vial from a grey-market bodybuilding supplier: often $40–$80. That gap raises identity, purity, and contamination questions.
Correct LR3 takes recombinant expression, correct disulfide folding, and a mass-spec identity confirming the full 83-residue molecule.
A CoA showing only generic native-hormone identity doesn't confirm the LR3 analog, so don't accept one. Pricing well below the research-reagent floor is a recognized sign of uncharacterized quality.
BPC-157 & tesamorelin
Peptriva stocks BPC-157 (15-residue VEGFR2-active tissue-repair peptide) and tesamorelin (the only FDA-approved GH-axis peptide) as third-party tested reference compounds for GH/IGF-1-axis and tissue-repair studies, without the IGF-1 LR3 cancer-biology concern. Both ship with batch-matched CoAs from ISO 17025 third-party labs.
Frequently asked questions
What is IGF-1 LR3?
A synthetic 83-amino-acid version of human insulin-like growth factor 1, carrying two modifications. A 13-residue front-end tail is the "Long" part. An arginine swap at position 3 is the "R3" part.
Those changes cut the binding of carrier proteins that normally hold over 95% of the native hormone. What you get is a longer-lasting peptide with far more free signal at its target.
It's sold as a research reagent, and widely diverted to grey-market bodybuilding with no human RCT behind it.
LR3 vs the native version (mecasermin / Increlex)
Mecasermin is the 70-amino-acid native hormone, unmodified. It's FDA-approved for severe pediatric deficiency, dosed twice daily because the natural buffer keeps the free fraction short-lived.
LR3 was engineered to dodge that buffer. Different sequence, different pharmacology, and only mecasermin carries FDA approval.
Is LR3 FDA-approved?
No. No FDA approval, no EMA approval, no approved use anywhere. Mecasermin, the native version, is the only FDA-approved therapy in this family, and it's restricted to severe pediatric deficiency. LR3 sells legally as a research reagent labeled for lab use only.
LR3 cancer risk: what's the concern?
Higher endogenous IGF-1 blood levels track with increased cancer risk in population studies, and signaling on this pathway switches on proliferative programs malignant cells exploit.
Chronic LR3 use produces higher and more sustained IGF-1R signaling than any natural state. No RCT quantifies that risk, so the concern is inferred from population epidemiology plus LR3's pharmacology.
The mecasermin label contraindicates active or suspected malignancy for the native, buffered form. LR3 amplifies the same signaling axis.
LR3 WADA status
Explicitly prohibited under WADA category S2.3, which covers growth factors and growth-factor modulators. That applies in and out of competition, and athletes face sanctions for documented use.
How does LR3 compare to CJC-1295 / ipamorelin for GH-axis research?
CJC-1295 and ipamorelin act upstream. They stimulate pituitary GH release, which drives liver IGF-1 production through the normal axis, with negative feedback intact.
LR3 skips all of that and binds the IGF-1 receptor directly, with much less IGFBP buffering in the way. Upstream secretagogues keep more of the regulatory machinery.
Tesamorelin is the only FDA-approved compound in the upstream GH-axis category. These compounds sit at different points on the same spectrum, and each carries its own risk profile.
How much does LR3 cost?
Research-reagent supplier pricing in 2026: $100–$250 per 1 mg vial. Grey-market bodybuilding pricing: often $40–$80 per 1 mg. The gap raises identity, purity, and contamination concerns for a peptide this hard to make correctly. We don't stock LR3.
What to know now
- IGF-1 LR3 is pharmacologically active. Long-acting, low carrier-protein binding, direct receptor activator. The structural pharmacology of the molecule is well-characterized in the literature.
- Zero human RCTs of IGF-1 LR3 for any use in healthy adults have been published in 2020–2026. All grey-market claims rest on extrapolation from IGF-1 biology, not direct LR3 trial data.
- The cancer-biology concern is the central issue. Chronic unbuffered IGF-1R signaling is the most pro-mitogenic configuration of a pathway population studies associate with elevated cancer incidence.
- The only FDA-approved IGF-1 therapy is mecasermin (Increlex). Native IGF-1. Twice-daily dosing. Severe pediatric deficiency only. Active malignancy is a contraindication.
- WADA prohibits IGF-1 and its analogs explicitly under S2.3, in-competition and out-of-competition. One of the most clearly enumerated prohibitions for any research peptide.
- Upstream GH-axis alternatives (CJC-1295, ipamorelin, tesamorelin) target the same pathway while preserving physiological negative-feedback regulation. Tesamorelin is the only FDA-approved compound in this category. Peptriva stocks tesamorelin and BPC-157; IGF-1 LR3 is not stocked.
What we're watching
What would change this analysis is independent human RCT data on chronic adult LR3 use. Properly powered, with follow-up long enough to detect cancer signals, meaning 5–10 years minimum. No visible clinical pipeline is doing that work.
FDA mecasermin label updates stay the most informative source on what supervised IGF-1-axis therapy looks like in practice.
We also track IGF-1 blocker development in oncology. Figitumumab, ganitumab and dalotuzumab have all run trials. The indications they target are inverse-direction evidence for what chronic IGF-1R activation might do. We read the money spent shutting this pathway down as a signal on its own.
References
- Engel, M. G., Narayan, S., Cui, M. H., et al. (2024). Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer’s Disease, 103(1), 113–126. https://doi.org/10.1177/13872877241299056
- White, A., Stremming, J., Boehmer, B. H., et al. (2021). Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect. American Journal of Physiology — Endocrinology and Metabolism, 320(6), E1138–E1147. https://doi.org/10.1152/ajpendo.00623.2020
- White, A., Stremming, J., Brown, L. D., & Rozance, P. J. (2023). Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of Developmental Origins of Health and Disease, 14(3), 353–361. https://doi.org/10.1017/S2040174423000090
- Jonker, S. S., Giraud, G. D., Chang, E. I., Elman, M. R., & Louey, S. (2020). Coronary vascular growth matches IGF-1-stimulated cardiac growth in fetal sheep. FASEB Journal, 34(8), 10041–10055. https://doi.org/10.1096/fj.202000215R
- Lu, Z., Liu, N., Huang, H., et al. (2023). Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied Microbiology and Biotechnology, 107(14), 4543–4551. https://doi.org/10.1007/s00253-023-12606-0
- U.S. Food and Drug Administration. (2019). Increlex (mecasermin [rDNA origin] injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021839s019lbl.pdf
- World Anti-Doping Agency. (2026). The Prohibited List — Category S2: Peptide hormones, growth factors, related substances and mimetics. https://www.wada-ama.org/en/prohibited-list